Prostanoid therapies in the management of pulmonary arterial hypertension. - Wikidata - wikimedia - TriplyDB

Prostanoid therapies in the management of pulmonary arterial hypertension.

Prostanoid therapies in the management of pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q35284318

about

Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension.Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.Management of acute subdural hematoma in a patient with portopulmonary hypertension on prostanoid therapy.Pulmonary hypertension: Molecular aspects of current therapeutic intervention and future direction.Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats.8% Capsaicin Patch as Analgesia for Severe Treprostinil Infusion Site Pain.Reoptimization of the Organocatalyzed Double Aldol Domino Process to a Key Enal Intermediate and Its Application to the Total Synthesis of Δ -Prostaglandin J Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial

P2860

Q28069093-4FD554CB-243D-4007-A122-6DF73551EC31 Q33788554-EFE9795F-52E9-4983-885F-25D61F23CD83 Q39317922-FB6950A6-E946-46FE-84BF-964C63AECE8F Q41339390-6FB7EA7A-FED9-4946-80DF-50024409AAEF Q47941425-0E744A1D-5AF9-41D1-A58B-04731449A8C1 Q50416961-CEB30917-2E6B-47F1-97AF-7231CB063B81 Q55044771-8238C425-4F99-4DB9-85B1-DEB88B194155 Q57214912-A2645F4C-CD0C-4F0C-9114-C31195122B98 Q58761710-19CBB0D9-B2C4-444B-A989-19CB6181176A

P2860

Prostanoid therapies in the management of pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q35284318

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Prostanoid therapies in the management of pulmonary arterial hypertension.

@ast

Prostanoid therapies in the management of pulmonary arterial hypertension.

@en

type

label

Prostanoid therapies in the management of pulmonary arterial hypertension.

@ast

Prostanoid therapies in the management of pulmonary arterial hypertension.

@en

prefLabel

Prostanoid therapies in the management of pulmonary arterial hypertension.

@ast

Prostanoid therapies in the management of pulmonary arterial hypertension.

@en

P1433

Q35284318-73B134C9-B8FA-42FB-8B8C-330A9A2212EC

P1476

Q35284318-0DED54E8-9B3B-4AE4-B6D0-EC2C597D7721

P2093

Q35284318-3D9FDE5A-2AF1-47E8-A9EB-438BD9B36C87

P2860

Q35284318-01769B5B-84F1-488E-8308-CEDA084A8D9A

Q35284318-04EEDF10-9D98-4AC8-B801-1E1379CDBBF8

Q35284318-0750798B-E73E-474F-B5CC-EBB3C8653F4C

Q35284318-084599B6-AB2D-48EC-9BA9-20526AC40F5F

Q35284318-0A277B9F-1196-4749-946F-D19A783EDF61

Q35284318-0BD5326B-F07D-43C9-ABA0-E1B6F9C7E46B

Q35284318-1684EF1C-C048-488D-AC07-529952F079BD

Q35284318-184B015D-0967-470B-8085-010310795B91

Q35284318-20F81F47-3E7B-4DAC-9243-1CC862C554EE

Q35284318-22A16D75-FEA7-4C76-BD62-F371D0AD5E45

P304

Q35284318-DE024EEC-59C5-41DD-9427-E13F0C2B4935

P31

Q35284318-38254EBD-EFE2-47F7-9F0A-9E5FA731D937

P356

Q35284318-F8DEFFF9-3CD1-43B4-B485-2F5D21A7AC43

P478

Q35284318-E5BEAEE0-8A48-48DF-A204-21FE59FC364B

P577

Q35284318-E0465053-9933-4B48-89F7-A62A213A2913

P5875

Q35284318-201304DC-70CA-46A0-AD71-9610AD2FDB35

P698

Q35284318-476E030B-86FD-4CB1-B226-82A341EE3A95

P932

Q35284318-E79F56A9-5D84-4D16-B06A-7B640E4524EB

P356

P1433

Therapeutics and Clinical Risk Management

P1476

Prostanoid therapies in the management of pulmonary arterial hypertension.

@en

P2093

Barbara L LeVarge

http://www.w3.org/2001/XMLSchema#string

P2860

Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension

Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin)

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

Bloodstream infections in patients given treatment with intravenous prostanoids.

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

Inhaled iloprost for severe pulmonary hypertension.

Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.

Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion.

Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis

An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.

P304

535-547

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S75122

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274644085

http://www.w3.org/2001/XMLSchema#string

P698

25848300

http://www.w3.org/2001/XMLSchema#string

P932

4386780

http://www.w3.org/2001/XMLSchema#string